Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its annual and special meeting of shareholders held earlier today.
2024年9月17日，新斯科舍省哈利法克斯（GLOBE NEWSWIRE）- Appili Therapeutics Inc.（TSX: APLI; OTCPink: APLIF）（以下簡稱「公司」或「Appili」）是一家專注於傳染性疾病和醫療對策藥物開發的生物製藥公司，今天宣佈了其年度和特別股東大會的結果，該會議於今天早些時候舉行。
Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Prakash Gowd.
根據收到的委託書和會議上的投票情況，公司股東通過了所有提交的決議，包括選舉以下董事連任：Don Cilla，Brian Bloom，Theresa Matkovits，Juergen Froehlich，Armand Balboni和Prakash Gowd。
Voting results for each director are summarized below:
各董事的投票結果如下：
| Name of Nominee | Percentage of Votes For | Percentage of Votes Against |
| Don Cilla | 27,929,188 (94.54%) | 1,612,685 (5.46%) |
| Brian Bloom | 28,409,188 (96.17%) | 1,132,685 (3.83%) |
| Theresa Matkovits | 29,377,973 (99.45%) | 163,900 (0.55%) |
| Juergen Froehlich | 29,377,973 (99.45%) | 163,900 (0.55%) |
| Armand Balboni | 28,409,188 (96.17%) | 1,132,685 (3.83%) |
| Prakash Gowd | 29,377,973 (99.45%) | 163,900 (0.55%) |
| 提名人姓名 | 贊成票百分比 | 投票反對的百分比 |
| 唐希拉 | 27,929,188 (94.54%) | 1,612,685 (5.46%) |
| Brian Bloom | 28,409,188 (96.17%) | 1,132,685 (3.83%) |
| Theresa Matkovits | 29,377,973股（佔99.45%） | 163,900股（佔0.55%） |
| Juergen Froehlich | 29,377,973股（佔99.45%） | 163,900股（佔0.55%） |
| Armand Balboni | 28,409,188股（佔96.17%） | 1,132,685股（佔3.83%） |
| 普拉卡什·高德 | 29,377,973 (99.45%) | 163,900 (0.55%) |
All other matters considered at the Meeting were approved by shareholders, including the re-appointment of PricewaterhouseCoopers, LLP, Chartered Accountants, as the independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration, a special resolution approving the Company's continuation (the "Continuance") from a corporation governed under the Canada Business Corporations Act to a corporation governed under the Business Corporations Act (Ontario) ("OBCA") and special resolution to authorize the board of directors of the Company, following the Continuance, to set the number of directors from time to time within the minimum and maximum number of directors set forth in the articles of the Company, in accordance with Section 125(3) of the OBCA.
股東們已批准了在會議上考慮的所有其他問題，包括再次任命普華永道有限責任合夥人會計師事務所作爲公司的獨立核數師，並授權公司董事會確定其報酬，特別決議批准公司繼續（「續存」）由加拿大公司法規管的公司轉變爲由安大略商業公司法（「OBCA」）管理的公司，並特別決議授權公司董事會在續存後根據公司章程規定的董事最低和最高人數，根據OBCA第125(3)條規定隨時確定董事人數。
The Company has filed a report of the voting results on all resolutions voted on the Meeting on the Company's SEDAR+ profile at .
公司已在公司的SEDER+資料檔案中提交了會議上所有決議投票結果的報告。
About Appili Therapeutics
關於Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit .
Appili Therapeutics是一家針對傳染病的生物製藥公司，旨在解決致命感染，其構建了有目標的組合投資組合並將人爲中心以履行其使命。通過系統地識別存在未滿足需求的緊急感染，Appili的目標是戰略性地開發一系列新型療法以預防死亡並改善生活。該公司目前正在推進各種抗感染藥物，包括經FDA批准的做好的甲硝唑懸浮液用於治療抗微生物感染，候選疫苗用於消除嚴重的生物武器威脅以及用於治療令人毀容的疾病的局部抗寄生蟲藥物。在一支經過驗證的管理團隊的領導下，Appili處於全球抗感染戰鬥的中心地帶。欲了解更多信息，請訪問。
Media Contact:
Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
媒體聯繫人：
Jenna McNeil，企業事務和通信經理
Appili Therapeutics
E：JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: Info@AppiliTherapeutics.com
投資者關係聯繫人：
唐希拉，藥學博士，M.B.A。
Appili Therapeutics
E: Info@AppiliTherapeutics.com
譯文內容由第三人軟體翻譯。